Neuvasq Biotechnologies, a privately held biotech founded in 2021, is advancing first-in-class disease-modifying antibodies to restore and protect the integrity of neurovascular barriers for healthy brain and retinal function. Neuvasq is developing novel solutions against neurological diseases, including drug-refractory epilepsy and Alzheimer’s disease. The company is headquartered in Gosselies, Belgium. For more information, please visit www.neuvasq.com.